Nivolumab for Stomach Cancer
This trial is testing an investigational drug in combination with chemotherapy to treat people with gastric or gastroesophageal junction cancer that can't be removed by surgery and has spread to other parts of the body.
- Stomach Cancer
- Esophagogastric Junction
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 3 trial • 541 Patients • NCT02041533
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Could you provide an estimate of the total participants enrolled in this clinical trial?
"Currently, no participants are being sought for this particular clinical trial. The study was initially posted on October 16th 2018 and was last amended November 3rd 2022. If you are in search of other studies, 631 medical trials recruiting patients with gastric cancer and 718 trials looking to enroll Nivolumab recipients exist at present."
Is this a pioneering endeavor in terms of clinical research?
"At present, there are 718 trials involving Nivolumab that are being conducted across 2354 cities and 49 nations. The initial experiment regarding this pharmaceutical was completed by Ono Pharmaceutical Co. Ltd in 2012, with 659 participants testing the drug's safety during its Phase 1 & 2 assessment period. Since then, 273 further clinical studies have been undertaken."
Are there any participating sites that are located in North America for this trial?
"This clinical trial has sites scattered across North America, including Local Institution in Kelowna, British Columbia; Dallas VA Medical Center in Quebec, Nova Scotia and Uc Irvine Medical Centre located in Halifax, Texas. Additionally there are 25 other medical centres participating."
Have any past studies been conducted involving Nivolumab treatment?
"Currently, there are 718 Nivolumab-based clinical trials in operation with 82 being Phase 3 evaluations. The majority of studies take place near Zürich BE; however, 40237 different sites are running related research initiatives."
Is there any risk associated with Nivolumab treatments?
"Based on the current scientific evidence, our team has assigned a score of 2 for Nivolumab's safety. This is due to Phase 2 trial data indicating that there may be some safety benefits but no efficacy yet established."
Are there still vacancies for prospective participants in this research project?
"This research project has closed its recruitment phase, with the initial posting on October 16th 2018 and final update on November 3rd 2022. Fortunately, there are 631 clinical trials recruiting patients suffering from stomach cancer and 718 separate studies seeking participants for treatment using Nivolumab."